Clinical Research Directory
Browse clinical research sites, groups, and studies.
Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Summary
This is a prospective, single-arm, single-center clinical trial designed to evaluate the safety and efficacy of radiation combined with a BCMA/CD3 bispecific antibody (CM336) in patients with solitary bone plasmacytoma (SBP) with mild bone marrow infiltration.
Official title: A Prospective Single-Arm Clinical Trial of Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration
Key Details
Gender
All
Age Range
18 Years - 78 Years
Study Type
INTERVENTIONAL
Enrollment
21
Start Date
2025-08-25
Completion Date
2027-12-01
Last Updated
2025-09-08
Healthy Volunteers
No
Interventions
BCMA/CD3 bispecific antibody (CM336)
Patients with solitary bone plasmacytoma (SBP) with mild bone marrow infiltration will receive radiation combined with a BCMA/CD3 bispecific antibody (CM336)
Locations (1)
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
Tianjin, China